查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1470903

癌症藥物市場：按適應症、藥物類別、給藥途徑、分銷和最終用途 - 2024-2030 年全球預測

Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年癌症治療市場規模為1,757.8億美元，2024年達1,884.1億美元，預計2030年將達2,944.2億美元，複合年成長率為7.64%。

癌症藥物是用於治療、診斷和預防癌症的特殊藥物。這些藥物透過各種作用機制靶向癌細胞，因此在惡性的治療中至關重要。癌症治療藥物分為多種類型，包括化療、標靶治療、免疫療法、荷爾蒙療法等，每種藥物在癌症治療中都扮演著獨特的角色。全球癌症發生率的快速上升，加上抗癌藥物開發的投資和政府資助的增加，正在推動市場成長。然而，新藥的開發、測試和獲得核准的成本對製造商構成了重大挑戰。此外，基因組定序技術和生物技術的進步，以及對個人化藥物的需求不斷增加，正在為市場成長創造利潤豐厚的機會。

主要市場統計
基準年[2023] 1757.8億美元
預測年份 [2024] 1884.1億美元
預測年份 [2030] 2944.2億美元
複合年成長率（%） 7.64%

由於藥物類別的高精度和較少的副作用，標靶治療變得越來越重要

化療涉及使用細胞毒性藥物來殺死癌細胞或阻止它們生長。化療是最古老的癌症治療方法之一，用於治療多種類型的癌症。對於晚期癌症或已擴散的癌症，化療通常是首選。化療可以單獨使用，也可以與其他治療方法合併使用。荷爾蒙療法透過阻止身體產生荷爾蒙的能力並阻止其作用來減緩或阻止荷爾蒙敏感腫瘤的生長。這種療法主要用於乳癌和攝護腺癌，這些癌症通常會隨著荷爾蒙的反應而生長。免疫療法增強人體對抗癌症的自然防禦能力。免疫療法使用體內或實驗室製造的物質來增強和恢復免疫系統功能。對於具有表明可能對這種治療有反應的標記的癌症，例如黑色素瘤、肺癌和腎癌，免疫療法是首選。標靶治療針對有助於癌症生長和存活的特定基因、蛋白質或組織環境。這種治療方法可以阻止癌細胞生長和擴散，同時限制對健康細胞的傷害。標靶治療特別適用於具有這些藥物可以針對的基因突變的癌症，例如某些類型的肺癌、乳癌和大腸癌。

最終用途癌症診所的擴張加速了對癌症藥物的需求

家庭醫療保健對癌症藥物的需求顯著增加。患者及其家人通常會發現居家醫療更加舒適，並減少了經常去醫院帶來的心理壓力。醫院是癌症藥物管理的重要終點，尤其是需要先進基礎設施和密切醫療監測的治療。該醫院治療多種癌症，並且經常治療需要住院治療的嚴重病例。癌症診所位於居家醫療和醫院之間，在門診環境中提供專門護理。這些診所對於癌症患者的持續治療和監測至關重要，並且通常可以輕鬆獲得最新藥物和臨床試驗。

區域洞察

受高醫療保健支出、強大的研發基礎設施和大型製藥公司的強大影響力，美洲地區是癌症藥物的主要市場。新型藥物輸送系統和標靶治療的專利凸顯了該國的創新，而對癌症研究和舉措的大量投資則強調了我們對根除癌症的承諾。歐洲市場的特點是統一的監管環境，為癌症藥物的開發和核准創造了有利的環境。該市場因成員國之間的價格敏感性而有所不同，需要創新的治療方法以及具有成本效益的癌症治療解決方案。中東和非洲地區呈現出多元化的市場環境，波灣合作理事會（GCC）國家對創新癌症治療表現出較高的購買力，而撒哈拉以南非洲國家則強調可近性和可負擔性。在中階不斷壯大、醫療保健支出不斷增加以及政府旨在改革醫療保健的舉措的推動下，亞太地區的癌症藥物市場正在迅速擴張。亞太地區國家在癌症研究和開發中發揮關鍵作用，在國內和全球癌症市場上取得了長足的進展。

FPNV定位矩陣

FPNV定位矩陣對於評估癌症藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對癌症治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.癌症治療藥物市場的市場規模與預測為何？

2.在癌症藥物市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.癌症藥物市場的技術趨勢和法規結構是什麼？

4.癌症治療藥物市場主要廠商的市場佔有率為何？

5.進入抗癌藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率正在迅速增加
      • 增加對癌症藥物開發的投資和政府資助
      • 擴大個人化醫療的研究與開發
    • 抑制因素
      • 精準醫學治療相關的高成本
    • 機會
      • 基因組序列分析技術和生物技術的進展
      • 生物標記主導藥物開發的進展
    • 任務
      • 嚴格的監管要求和藥物開發的複雜性
  • 市場區隔分析
    • 藥物類別：由於準確性和副作用較少，標靶治療變得越來越重要
    • 最終用途：癌症診所的持續擴張加速了癌症藥物的需求
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章以適應症分類的癌症治療藥物市場

  • 膀胱癌
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 食道癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 攝護腺癌
  • 胃癌

第7章按藥物類別分類的癌症藥物市場

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 標靶治療

第8章癌症藥物市場：依途徑

  • 靜脈
  • 口服
  • 話題

第9章 癌症治療藥物市場經銷商

  • 線下藥局
  • 網路藥房

第10章癌症藥物市場：依最終用途分類

  • 家庭保健
  • 醫院
  • 癌症專科診所

第11章：美洲的癌症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區抗癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的癌症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准XTANDI 用於高風險前列腺癌治療
    • 武田製藥的 FRUZAQLA 獲得 FDA核准用於治療轉移性大腸癌
    • FDA核准武田製藥的 FRUZAQLA，一種治療轉移性大腸直腸癌的新療法
  • 戰略分析和建議

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-434CCDA05255

[194 Pages Report] The Oncology Drugs Market size was estimated at USD 175.78 billion in 2023 and expected to reach USD 188.41 billion in 2024, at a CAGR 7.64% to reach USD 294.42 billion by 2030.

Oncology drugs are specialized pharmaceutical agents used in the treatment, diagnosis, and prevention of cancer. These drugs are pivotal in the management of malignancies as they target cancer cells with various mechanisms of action. Oncology drugs can be categorized into several types, including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others, each playing a unique role in oncology care. The surging prevalence of cancer worldwide, coupled with the increase in investments and government funding in the development of cancer drugs, propel the market growth. However, the cost of developing, testing, and securing regulatory approval for new drugs poses a significant challenge to the manufacturers. Furthermore, advancements in genomic sequencing technologies and biotechnology, along with the growing need for personalized medicines, create lucrative opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 175.78 billion
Estimated Year [2024] USD 188.41 billion
Forecast Year [2030] USD 294.42 billion
CAGR (%) 7.64%

Drug Class: Growing significance of targeted therapy due to its precision and lower side effects

Chemotherapy involves the utilization of cytotoxic drugs to kill or hamper the growth of cancer cells. It is among the oldest forms of cancer treatment and can be used across various cancer types. Chemotherapy is often preferred for advanced cancers or cancers that have metastasized. It can be used as a sole treatment & in combination with other therapies. Hormonal therapy slows or prevents the growth of hormone-sensitive tumors by stopping the body's ability to produce hormones & by interfering with hormone action. This therapy is primarily used for breast and prostate cancers, which often grow in response to hormones. Immunotherapy boosts the body's natural defenses to combat cancer. It utilizes substances made by the body or in a laboratory to enhance and restore immune system function. Immunotherapy is preferred for cancers that have markers indicating they may respond to this treatment, such as melanoma, lung cancer, and kidney cancer. Targeted therapy targets the specific genes, proteins, or the tissue environment contributing to cancer growth and survival. This type of therapy stops the growth and prevalence of cancer cells while limiting damage to healthy cells. Targeted therapy is specifically used for cancers with genetic mutations that can be targeted with these drugs, such as certain types of lung, breast, and colorectal cancers.

End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs

Home healthcare has seen a significant uptick in the demand for oncology drugs, attributed largely to the increasing preference for at-home treatments. Patients and families often find home healthcare options more comfortable, reducing the psychological stress associated with frequent hospital visits. Hospitals remain a critical endpoint for the administration of oncology drugs, especially for treatments that require advanced infrastructure and close medical supervision. They cater to a wide spectrum of cancers, often dealing with more severe cases that necessitate in-patient care. Specialty cancer clinics offer a middle ground between home healthcare and hospitals, providing specialized care in an outpatient setting. These clinics are pivotal for the ongoing treatment and monitoring of cancer patients, often facilitating access to the latest drugs and clinical trials.

Regional Insights

The American region represents a major market for oncology drugs, driven by high healthcare expenditure, robust research and development infrastructure, and a strong presence of leading pharmaceutical companies. Patents in novel drug delivery systems and targeted therapies highlight the country's innovation, while significant investment in cancer research & initiatives underscores a commitment to combating cancer. The European market is marked by a harmonized regulatory landscape that fosters a conducive environment for oncology drug development and approval. Differentiated by price sensitivity across member states, the market demands cost-effective oncology solutions alongside innovative therapies. The Middle East & Africa region presents a diverse market landscape, with Gulf Cooperation Council (GCC) countries showing high purchasing power for innovative oncology treatments, contrasted with Sub-Saharan Africa's focus on accessibility and affordability. The APAC region's oncology drugs market is rapidly expanding, fueled by a growing middle class, increased healthcare spending, and government initiatives aimed at healthcare reform. The APAC countries with significant players in oncology research and development are making strides in both the domestic and global oncology markets.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Oncology Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncology Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Esophagus Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • Stomach Cancer
  • Drug Class
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Targeted Therapy
  • Route of Administration
    • Intravenous
    • Oral
    • Topical
  • Distribution
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • End-use
    • Home Healthcare
    • Hospitals
    • Specialty Cancer Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Oncology Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncology Drugs Market?

3. What are the technology trends and regulatory frameworks in the Oncology Drugs Market?

4. What is the market share of the leading vendors in the Oncology Drugs Market?

5. Which modes and strategic moves are suitable for entering the Oncology Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of cancer across the globe
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Growing research & development in personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the precision medicine therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic sequencing technologies and biotechnology
      • 5.1.3.2. Development of biomarker-driven drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and the complexity of drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
    • 5.2.2. End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Oncology Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Breast Cancer
  • 6.4. Cervical Cancer
  • 6.5. Colorectal Cancer
  • 6.6. Esophagus Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Lung Cancer
  • 6.10. Prostate Cancer
  • 6.11. Stomach Cancer

7. Oncology Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Immunotherapy
  • 7.5. Targeted Therapy

8. Oncology Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Oncology Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
  • 9.3. Online Pharmacies

10. Oncology Drugs Market, by End-use

  • 10.1. Introduction
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Specialty Cancer Clinics

11. Americas Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves XTANDI for High-Risk Prostate Cancer Management
    • 14.3.2. Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance
    • 14.3.3. FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ONCOLOGY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 299. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 300. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 325. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 326. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 337. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 338. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 349. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 350. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 355. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 356. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 357. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 358. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 359. FRANCE ONCOLOGY DRUGS